Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Lacrimal Apparatus Diseases 1Lacerations 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endophthalmitis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 26Nivolumab 10Docetaxel 8avelumab 7atezolizumab 7Gemcitabine 7Carboplatin 6Trastuzumab 5Ipilimumab 5Radiosurgery 4Psychiatric Rehabilitation 4Immunoglobulin G 4Early Intervention, Educational 4Cyclophosphamide 4fludarabine 3durvalumab 3cemiplimab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Disulfides 3Counseling 3Cisplatin 3Blood Specimen Collection 3Biopsy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3zimberelimab 2utomilumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Cyclosporins × Thoracic × Clear all
NCT00824811 2012-08-02

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

M.D. Anderson Cancer Center

Phase 2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Lacrimal Apparatus Diseases, Lung Neoplasms, Endophthalmitis, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Lacerations, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡